Phases two and three of Food and Drug Administration approved trials of a drug developed to stop the traditional “boot camp crud” kicked off last month. The drug could eventually reduce illness in as many as one-fifth of recruits entering the Navy. The adenoviral illness is caused by viral pathogens, said Cmdr. Kevin Russell, the Navy’s lead physician overseeing the Navy’s portion of the Army-led joint Army/Navy trials. To ensure safety and effectiveness, several trials must be conducted before the vaccine is licensed by the FDA. Phase one, with 58 volunteer Army medics as subjects, was completed in 2004. Russell said phases two and three should be finished in late 2007. He added that 10 to 20 percent of all recruits lose some time from training due to adenoviral illness, impacting recruit training success and readiness.